UBS Raises Price Target on Johnson & Johnson to $320
On September 2, 2026, UBS analyst Michael Yee upgraded his rating for Johnson & Johnson (JNJ) to Buy while increasing the price target to $320 from a prior $280. This adjustment reflects a significant increase of 14.29%. JNJ is currently trading at $277.94, which is 44.1% overvalued compared to its GF Value™ of $192.90.
The company's strong overall performance is reflected in its GF Score™ of 83/100. However, the significant insider selling and mixed guru activity signal potential risks for investors. According to GuruFocus, JNJ generates just over half of its total revenue from the United States, highlighting its strong domestic presence.
Johnson & Johnson operates primarily in the Drug Manufacturers industry and has recently undergone significant restructuring, focusing on three main therapeutic areas: immunology, oncology, and neurology. The company's standout sub-ranks include a profitability rank of 9/10 and a growth rank of 8/10, indicating robust financial health and potential for future expansion.
With 24 gurus holding positions in JNJ, 5 adding to their stakes, and 14 trimming their holdings in recent quarters, the mixed activity suggests a cautious sentiment among institutional investors. Given the current overvaluation of JNJ, as indicated by the GF Value™ and the high P/E ratio compared to historical norms, investors may want to exercise caution.